Expertise in
26
conditions

Dr. Mariko Sato

Pediatric Hematology Oncology
1201 West La Veta Avenue, 
Orange, CA 
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
Referral may be required
Before you request
Expertise in
26
conditions
1201 West La Veta Avenue, 
Orange, CA 

Overview

Mariko Sato is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California.

Dr. Sato is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Glioma, Medulloblastoma, Hepatoblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 21 peer reviewed articles and participating in 68 clinical trials. Dr. Sato is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in UT

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

1201 West La Veta Avenue, Orange, CA 92868

Additional Areas of Focus

Dr. Sato has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

68 Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Enrollment Status: Recruiting
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 2
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
View 4 Less Clinical Trials

21 Total Publications

Unusual Magnetic Resonance Imaging (MRI) Features of Neonatal Facial Nerve Palsy.
Unusual Magnetic Resonance Imaging (MRI) Features of Neonatal Facial Nerve Palsy.
Journal: Journal of child neurology
Published: August 08, 2025
Similar Doctors
Expertise in
16
conditions
Dr. Elyssa M. Rubin
Pediatric Hematology Oncology
Expertise in
16
conditions
Dr. Elyssa M. Rubin
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elyssa Rubin is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Rubin is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Aspiration. Dr. Rubin is currently accepting new patients.

Expertise in
17
conditions
Dr. Diane J. Nugent
Pediatric Hematology Oncology
Expertise in
17
conditions
Dr. Diane J. Nugent
Pediatric Hematology Oncology
Referral required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Diane Nugent is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Nugent is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Blood Clots, Hemophilia A, Immune Thrombocytopenic Purpura (ITP), and Mast Cell Activation Syndrome (MCAS). Dr. Nugent is currently accepting new patients.

Expertise in
17
conditions
Dr. Pournima D. Navalkele
Pediatric Hematology Oncology
Expertise in
17
conditions
Dr. Pournima D. Navalkele
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Pournima Navalkele is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Navalkele is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Medulloblastoma, Glioma, Acute Lymphoblastic Leukemia (ALL), and Ganglioglioma. Dr. Navalkele is currently accepting new patients.

Expertise in
15
conditions
Dr. Josephine H. Haduong
Pediatric Hematology Oncology
Expertise in
15
conditions
Dr. Josephine H. Haduong
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Josephine Haduong is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Haduong is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Rhabdomyosarcoma, Hepatoblastoma, Acute Lymphoblastic Leukemia (ALL), and Neuroblastoma. Dr. Haduong is currently accepting new patients.

Expertise in
9
conditions
Dr. Rishikesh S. Chavan
Pediatric Hematology Oncology
Expertise in
9
conditions
Dr. Rishikesh S. Chavan
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rishikesh Chavan is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Chavan is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Hemophagocytic Lymphohistiocytosis, Virus Associated Hemophagocytic Syndrome, Graft Versus Host Disease (GvHD), and Bone Marrow Transplant. Dr. Chavan is currently accepting new patients.

Expertise in
17
conditions
Dr. Carol H. Lin
Pediatric Hematology Oncology
Expertise in
17
conditions
Dr. Carol H. Lin
Pediatric Hematology Oncology
Referral may be required
Before you request
1201 West La Veta Avenue, 
Orange, CA 
 (0.1 miles away)
714-509-8636
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carol Lin is a Pediatric Hematologist Oncology provider practicing medicine in Orange, California. Dr. Lin is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Hemophagocytic Lymphohistiocytosis, Virus Associated Hemophagocytic Syndrome, and Osteosarcoma. Dr. Lin is currently accepting new patients.

Frequently Asked Questions about Dr. Mariko Sato

How do I make an appointment with Dr. Mariko Sato?

You can book an appointment with Dr. Mariko Sato by calling their office at 714-509-8636. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mariko Sato a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mariko Sato is classified as an Distinguished expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mariko Sato specialize in?

While Dr. Mariko Sato is a Pediatric Hematology Oncology, they have specific expertise in Glioma, Medulloblastoma, and Hepatoblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Mariko Sato participate in research or clinical trials?

Yes. Dr. Mariko Sato has published 21 articles and abstracts on conditions like Glioma. You can view a list of Dr. Mariko Sato's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mariko Sato accept my insurance?

Dr. Mariko Sato accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-509-8636 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sato's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile